Success Stories

HuCAL Technology has demonstrated great success in creating human Fab and Ig monoclonal antibodies over the last ten years. So far we have produced over 14,000 antibodies and completed ~1000 projects.

Over the last 3 years, we have continuously achieved success rates of over 90% for HuCAL projects.

AbD Serotec has successfully generated and licensed HuCAL antibodies for a wide range of purposes:

• In vivo and in vitro research
• Diagnostic immunoassay development
• In vivo diagnostic assay development
• Preclinical and clinical drug monitoring in pharmacokinetic (PK) and anti-drug assays (ADA)
• Quality control release assays for drugs and vaccines
• Food testing
• Biodefense assays
• Medical devices

Customer Testimonials

“We were extremely happy with the timelines and the services provided by the HuCAL team and so we have commissioned another 3 projects!” -Mark Donovan, L’Oreal Research (L’Oreal, a worldwide leader in cosmetics, seeks to develop products of optimal safety and to participate in the development of methods that do not involve testing on animals.)

“We are very impressed by the services of AbD Serotec. They rapidly generated high affinity antibodies for 5 very challenging multispan human integral membrane proteins which we are currently evaluating in crystallization and functional studies”. -Par Nordlund, Karolinska Institute, Sweden

“We are all very impressed with the quality and efficiency of the work and our only regret is that we did not start the project much earlier” -Dr. Scott Fry, Alere® (Inverness Medical Australia Pty Ltd)

“We are pleased with these Abs. You’ve accomplished in a few months what a year of rat immunizations has not!” -Dr. Damon Asher, University of Massachusetts, USA

“I have definitely been impressed by the quality of your reagents and the speed for delivering new Fab antibodies. Furthermore, I really appreciated your flexibility and willingness to satisfy customer requests.” -Dr. Emmanuel Claret, Head of HTRF New Product Development, Cisbio international, France

Corporate Partners

Additionally, many prominent pharmaceutical and biotechnology companies from around the world are already using HuCAL technology by partnering with our parent company, MorphoSys. They have used our technology to create therapeutic antibodies, antibody sandwich pairs for biomarker validation, human antibody controls in autoimmune IVD kits, and anti-drug antibodies for pre-clinical & clinical monitoring in pharmacokinetic and immune response assays, as well antibodies for many other applications.

• Bayer (USA)
• Boehringer-Ingelheim (Germany)
• Bristol-Myers Squibb (USA)
• Centocor, Inc. (USA)
• Daiichi Sankyo & Co., Ltd. (Japan)
• GPC Biotech AG (Germany)
• Hoffman-LaRoche AG (Switzerland)
• Immunogen, Inc. (USA)
• Merck & Co., Inc. (USA)
• Novartis AG (Switzerland)
• Novoplant GmbH (Germany)
• Pfizer, Inc. (USA)
• Phadia AB (Sweden)
• Proteomika S.L. (Spain)
• Schering AG (Germany)
• Schering-Plough (USA)
• Shionogi & Co., Ltd. (Japan)
• Xoma Ltd. (USA)